Would you consider induction plus concurrent paclitaxel-RT to downstage a patient with initially unresectable cutaneous angiosarcoma, or do you reserve this approach for patients already deemed surgical candidates?

Induction paclitaxel is a standard approach and should be considered for all patients for whom medical comorbidity does not preclude its use. It is critical that the radiation oncologist evaluate the patient prior to chemotherapy so that the extent of disease can be appreciated prior to cytoreductio...

In the abstract presented, patients received induction paclitaxel-RT, and then surgical resection was performed when feasible, with findings of pathologic complete response in 10/18 (56%) resected patients. It’s not clear if all the patients were clearly resectable upfront, and given the very small ...